MASCC Risk Index for Febrile Neutropenia

The Multinational Association for Supportive Care in Cancer (MASCC) risk index identifies low-risk febrile neutropenia patients suitable for outpatient oral antibiotic therapy. Score 0-26.

Warnings:
  • MASCC >=21 predicts >91% of patients who do not have serious medical complications during febrile neutropenia
  • However, high MASCC does NOT guarantee absence of bacteremia or sepsis
  • False positive rate: 8.6% (some patients with score >=21 develop serious complications)
  • Must only be used after thorough clinical evaluation in stable patients
  • Recommended outpatient regimen: oral moxifloxacin OR amoxicillin-clavulanate + ciprofloxacin
  • Exclusion criteria for outpatient therapy: hemodynamic instability, pneumonia, severe abdominal pain, CNS symptoms, or clinically unstable
  • Some experts consider additional 3 points if burden is moderate without symptoms
Note: Maximum score = 26. Burden of illness scoring: No/mild = 5; Moderate = 3; Severe = 0. Developed in 2000 and validated internationally. Core questions are burden of illness, hypotension, COPD, solid tumor type, dehydration, outpatient status, and age.
No symptoms or mild symptoms = 5; moderate symptoms = 3; severe symptoms = 0 (no outpatient treatment)
Systolic blood pressure >=90 mmHg without supportive measures
No history of chronic obstructive pulmonary disease
Solid tumor or no prior fungal infection = 4; hematologic malignancy with previous fungal infection = 0
No clinical or radiographic evidence of dehydration
Patient was outpatient at onset of fever
Age less than 60 years

Medical Disclaimer

This calculator is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.